BIIB vs. JAZZ: Biogen vs. Jazz Pharmaceuticals Stock Comparison
How do Biogen (BIIB) and Jazz Pharmaceuticals (JAZZ) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Biogen (BIIB) and Jazz Pharmaceuticals (JAZZ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIIB is classified in Biotechnology while JAZZ is classified in Pharmaceuticals.
| Profile Item | BIIB | JAZZ |
|---|---|---|
| Name | Biogen Inc. | Jazz Pharmaceuticals plc |
| Country/Region | United States | Ireland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Pharmaceuticals |
| GICS Sub-Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 36.71 billion USD | 15.07 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | September 17, 1991 | June 1, 2007 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BIIB | JAZZ |
|---|---|---|
| Total Return (1Y) | 65.44% | 84.44% |
| Total Return (3Y, Annualized) | 4.62% | 27.57% |
| Total Return (5Y, Annualized) | -0.96% | 12.88% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | BIIB | JAZZ |
|---|---|---|
| Volatility (1Y, Annualized) | 34.58% | 38.74% |
| Beta (5Y) | 0.08 | 0.33 |
| Max Drawdown (5Y) | -64.35% | -42.03% |
| Avg. Volume (3M) | 1.05M | 878.80K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BIIB | JAZZ |
|---|---|---|
| Sharpe Ratio (1Y) | 1.77 | 2.07 |
| Sortino Ratio (1Y) | 2.77 | 4.14 |
Profitability
ROE (TTM)
Both Biogen (BIIB) at 1.87% and Jazz Pharmaceuticals (JAZZ) at 5.05% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.87%
- Max
- 109.18%
- Q3
- 6.23%
- BIIB
- 1.87%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.05%
- Max
- 109.18%
- Q3
- 6.23%
- JAZZ
- 5.05%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Biogen (BIIB) at 3.38% and Jazz Pharmaceuticals (JAZZ) at 4.37% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.38%
- Max
- 18.05%
- Q3
- 4.78%
- BIIB
- 3.38%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.37%
- Max
- 18.05%
- Q3
- 4.78%
- JAZZ
- 4.37%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Biogen (BIIB) at 24.12% and Jazz Pharmaceuticals (JAZZ) at 30.17% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
24.12%
- Max
- 83.12%
- BIIB
- 24.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.17%
- Max
- 83.12%
- JAZZ
- 30.17%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | BIIB | JAZZ |
|---|---|---|
| ROE (TTM) | 1.87% | 5.05% |
| ROA (TTM) | 4.94% | 6.92% |
| Net Margin (TTM) | 3.38% | 4.37% |
| Operating Margin (TTM) | 24.12% | 30.17% |
| Gross Margin (TTM) | 75.77% | 91.10% |
Growth
Revenue Growth
Both Biogen (BIIB) at 2.22% and Jazz Pharmaceuticals (JAZZ) at 4.88% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Biogen (BIIB) at -21.38% is around its peer norm for EPS growth, while Jazz Pharmaceuticals (JAZZ) at -167.51% drops into the bottom quartile, signaling weaker earnings momentum.
Growth Metrics
| Metric | BIIB | JAZZ |
|---|---|---|
| Revenue Growth (YoY) | 2.22% | 4.88% |
| Revenue Growth (3Y CAGR) | -0.94% | 5.26% |
| EPS Growth (YoY) | -21.38% | -167.51% |
| EPS Growth (3Y CAGR) | -25.04% | -- |
Financial Strength
Current Ratio (MRQ)
Both Biogen (BIIB) at 1.95 and Jazz Pharmaceuticals (JAZZ) at 1.82 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.95
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- BIIB
- 1.95
- Min
- 0.10
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.82
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- JAZZ
- 1.82
- Min
- 0.10
Debt / Equity (MRQ)
Biogen (BIIB) at 0.41 carries an industry-typical debt-to-equity mix, while Jazz Pharmaceuticals (JAZZ) at 1.35 uses more debt funding than most peers.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.41
- Max
- 1.42
- Q3
- 0.65
- BIIB
- 0.41
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 1.42
- JAZZ
- 1.35
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BIIB | JAZZ |
|---|---|---|
| Current Ratio (MRQ) | 1.95 | 1.82 |
| Debt / Equity (MRQ) | 0.41 | 1.35 |
| Net Debt / EBITDA | 1.97 | 1.39 |
Dividends
Dividend Yield (TTM)
Neither Biogen (BIIB) nor Jazz Pharmaceuticals (JAZZ) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIIB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Biogen (BIIB) nor Jazz Pharmaceuticals (JAZZ) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIIB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BIIB | JAZZ |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Both look expensive on trailing earnings: Jazz Pharmaceuticals (JAZZ) at 69.46 sits in the richer P/E ratio quartile, and Biogen (BIIB) at 107.51 is richer still, above its industry range.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
107.51
- BIIB
- 107.51
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
69.46
- Max
- 85.34
- JAZZ
- 69.46
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Biogen (BIIB) at 3.57 and Jazz Pharmaceuticals (JAZZ) at 3.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.57
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- BIIB
- 3.57
- Q1
- 3.01
- Min
- 0.01
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.19
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- JAZZ
- 3.19
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Biogen (BIIB) at 1.94 and Jazz Pharmaceuticals (JAZZ) at 3.59 are valued close to their industries’ norm against book — neither stands out from peers.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.94
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- BIIB
- 1.94
- Q1
- 1.69
- Min
- -5.59
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.59
- Max
- 13.53
- Q3
- 6.54
- JAZZ
- 3.59
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | BIIB | JAZZ |
|---|---|---|
| P/E Ratio (TTM) | 107.51 | 69.46 |
| P/S Ratio (TTM) | 3.57 | 3.19 |
| P/B Ratio (MRQ) | 1.94 | 3.59 |
| Free Cash Flow Yield (TTM) | 2.20% | 11.16% |